Scholarlink

Monoclonal antibodies have revolutionized cancer therapy and are integral part of standard therapies. Despite their clinical efficacy, not all cancer patients benefit from established antibody therapies. Preclinical and clinical findings revealed that Fc-mediated effector functions play an essential role in antibody therapy. Therefore, current antibody-based immunotherapies can be optimized by antibody Fc engineering to generate next-generation monoclonal antibodies with tailor-made effector functions. The enhancement of Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) may increase efficiency of prospective antibody-based immunotherapies.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector Functions

  • 实验方案

  • 发表日期：

    2026年

查看全文
  • Carina Lynn Gehlert,
  • Steffen Krohn,
  • Dorothee Winterberg,
  • Ammelie Svea Boje,
  • Thomas Theocharis,
  • Alexander Jochimsen,
  • Marta Lustig,
  • Thomas Valerius,
  • Christian Kellner,
  • Katja Klausz,
  • Matthias Peipp

摘要

Monoclonal antibodies have revolutionized cancer therapy and are integral part of standard therapies. Despite their clinical efficacy, not all cancer patients benefit from established antibody therapies. Preclinical and clinical findings revealed that Fc-mediated effector functions play an essential role in antibody therapy. Therefore, current antibody-based immunotherapies can be optimized by antibody Fc engineering to generate next-generation monoclonal antibodies with tailor-made effector functions. The enhancement of Fc-mediated effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and complement-dependent cytotoxicity (CDC) may increase efficiency of prospective antibody-based immunotherapies.